您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Sapitinib(AZD8931)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sapitinib(AZD8931)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sapitinib(AZD8931)图片
CAS NO:848942-61-0
包装:2mg, 5mg, 10mg, 50mg
包装与价格:
包装价格(元)
Free Sample (0.5-1 mg)电议
10mM*1mL in DMSO电议
2mg电议
5mg电议
10mg电议
50mg电议

产品名称
AZD-8931
产品介绍

生物活性

AZD8931 (Sapitinib)是一种可逆的,ATP竞争性EGFR, ErbB2和ErbB3抑制剂,IC50分别为4 nM, 3 nM和4 nM,作用于NSCLC细胞比Gefitinib或Lapatinib更有效,作用于ErbB家族比作用于MNK1和Flt选择性强100倍。AZD8931作用于NSCLC和SCCHN 细胞系的效果不同。AZD8931高度选择性作用于 PC-9细胞(EGFR 激活突变型),GI50为0.1 nM,而低活性作用于 NCI-1437细胞,GI50 >10 μM。与lapatinib 或 gefitinib相比,AZD8931作用于 PE/CA-PJ41, PE/CA-PJ49, DOK 和FaDu细胞,更有效作用于p-EGFR, p-erbB2 和 p-erbB3。


化学数据

分子量473.93
分子式C23H25ClFN5O3
CAS号848942-61-0
纯度>99%
溶解性(25°C)DMSO 40 mg/mL
储存和运输条件固体粉末: -20°C 冷藏长期储存
常温运输及临时存放

实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)

细胞实验
细胞系a panel of NSCLC and SCCHN cell lines: KYSE-30, OE21, PE/CA-PJ15, PE/CA-PJ34 (clone C12), PE/CA-PJ41 (clone D2), PE/CA-PJ49, DOK, Detroit562, RPMI2650, SCC-4, SCC-9, SCC-25, CAL 27, SW579, FaDu, Hs 840.T, KB, KYSE-450, and HEp-2, HN5; PC-9, Calu-3, NCI-H2073, NCI-H1623, NCI-H522, NCI-H2085, NCI-H2030, NCI-H1703, NCI-H2291, NCI-H2135, NCI-H1975, NCI-H23, NCI-H1650, NCI-H1437, NCI-H3255, and NCI-H1666 cell lines
方法cell viability assay. To determine their antiproliferative activity against cell lines grown in vitro, AZD8931, gefitinib, and lapatinib were tested in a panel of NSCLC and SCCHN cell lines. Cells were incubated for 96 h with a suitable range of concentrations of drug to ensure accurate estimation of the inhibitor concentration required to give 50% growth inhibition (GI50; typically between 0.001-10 μmol/L). Viable cell number was determined by 4 h of incubation with MTS Colorimetric Assay reagent (Promega) and absorbance measured at 490 nm on a spectrophotometer (Molecular Devices). Each experiment was carried out in triplicate for each drug concentration and data are presented as geometric means. Sensitivity groupings of GI50 data were<1 μmol/L (classed as sensitive), 1 to 7 μmol/L (classed as intermediate), and >7 μmol/L (classed as resistant).
浓度0~10μM
处理时间96 h

动物实验
动物模型BT474c, Calu-3, LoVo, FaDu and PC-9 xenograft mouse models
配制suspended in a 1% (v/v) solution of polyoxyethylenesorbitan monooleate (Tween 80) in deionized water
剂量6.25-50 mg/kg twice daily
给药处理oral gavage

不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

小鼠大鼠豚鼠仓鼠
重量 (kg)0.020.151.80.40.0810
体表面积 (m2)0.0070.0250.150.050.020.5
Km系数36128520
动物 A (mg/kg) = 动物 B (mg/kg) × 动物 B的Km系数
动物 A的Km系数

例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。


储备液配制

以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。

Concentration / Solvent Volume / Mass1 mg5 mg10 mg
1 mM2.11 mL10.5501 mL21.1002 mL
5 mM0.422 mL2.11 mL4.22 mL
10 mM0.211 mL1.055 mL2.11 mL